Literature DB >> 20508910

[Radiotherapy of hepatic metastases].

S E Combs1, K K Herfarth, D Habermehl, J Debus.   

Abstract

Non-invasive treatment of hepatic metastases has become a focal point of interdisciplinary oncology especially since the advent of stereotactic radiation techniques. Worldwide several centers have shown that this treatment is a curative and well tolerated regimen with excellent rates of local control. Modern devices which combine radiation therapy with imaging techniques (image-guided radiotherapy) in particular allow precise dose application, especially for hypofractionated treatment concepts requiring daily repositioning.

Entities:  

Mesh:

Year:  2010        PMID: 20508910     DOI: 10.1007/s00104-010-1889-3

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  32 in total

1.  Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy.

Authors:  C C Olsen; J Welsh; B D Kavanagh; W Franklin; M McCarter; H R Cardenes; L E Gaspar; T E Schefter
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-11-05       Impact factor: 7.038

2.  Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases.

Authors:  Alan W Katz; Madeleine Carey-Sampson; Ann G Muhs; Michael T Milano; Michael C Schell; Paul Okunieff
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-12-29       Impact factor: 7.038

3.  Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study.

Authors:  Alejandra Méndez Romero; Wouter Wunderink; Shahid M Hussain; Jacco A De Pooter; Ben J M Heijmen; Peter C J M Nowak; Joost J Nuyttens; Rene P Brandwijk; Cees Verhoef; Jan N M Ijzermans; Peter C Levendag
Journal:  Acta Oncol       Date:  2006       Impact factor: 4.089

4.  The use of 3-D dose volume analysis to predict radiation hepatitis.

Authors:  T S Lawrence; R K Ten Haken; M L Kessler; J M Robertson; J T Lyman; M L Lavigne; M B Brown; D J DuRoss; J C Andrews; W D Ensminger
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

5.  Four-dimensional radiotherapy planning for DMLC-based respiratory motion tracking.

Authors:  Paul J Keall; Sarang Joshi; S Sastry Vedam; Jeffrey V Siebers; Vijaykumar R Kini; Radhe Mohan
Journal:  Med Phys       Date:  2005-04       Impact factor: 4.071

6.  Noninvasive patient fixation for extracranial stereotactic radiotherapy.

Authors:  F Lohr; J Debus; C Frank; K Herfarth; O Pastyr; B Rhein; M L Bahner; W Schlegel; M Wannenmacher
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-09-01       Impact factor: 7.038

7.  Patterns of recurrence after curative-intent radiation for oligometastases confined to one organ.

Authors:  Michael T Milano; Alan W Katz; Paul Okunieff
Journal:  Am J Clin Oncol       Date:  2010-04       Impact factor: 2.339

8.  Treatment of cerebral metastases from breast cancer with stereotactic radiosurgery.

Authors:  Stephanie E Combs; Daniela Schulz-Ertner; Christoph Thilmann; Lutz Edler; Jürgen Debus
Journal:  Strahlenther Onkol       Date:  2004-09       Impact factor: 3.621

9.  Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients.

Authors:  H Blomgren; I Lax; I Näslund; R Svanström
Journal:  Acta Oncol       Date:  1995       Impact factor: 4.089

10.  Potential of image-guidance, gating and real-time tracking to improve accuracy in pulmonary stereotactic body radiotherapy.

Authors:  Matthias Guckenberger; Thomas Krieger; Anne Richter; Kurt Baier; Juergen Wilbert; Reinhart A Sweeney; Michael Flentje
Journal:  Radiother Oncol       Date:  2008-10-04       Impact factor: 6.280

View more
  3 in total

Review 1.  Individualized radiotherapy (iRT) concepts for locally advanced pancreatic cancer (LAPC): indications and prognostic factors.

Authors:  Stephanie E Combs
Journal:  Langenbecks Arch Surg       Date:  2015-07-03       Impact factor: 3.445

2.  Radiotherapeutic Options for Symptom Control in Breast Cancer.

Authors:  Birgitt van Oorschot; Gabriele Beckmann; Wolfgang Schulze; Dirk Rades; Petra Feyer
Journal:  Breast Care (Basel)       Date:  2011-02-14       Impact factor: 2.860

3.  Evaluation of inter- and intrafractional motion of liver tumors using interstitial markers and implantable electromagnetic radiotransmitters in the context of image-guided radiotherapy (IGRT) - the ESMERALDA trial.

Authors:  Daniel Habermehl; Patrick Naumann; Rolf Bendl; Uwe Oelfke; Simeon Nill; Jürgen Debus; Stephanie E Combs
Journal:  Radiat Oncol       Date:  2015-07-14       Impact factor: 3.481

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.